Stock Analysis

Insiders Sold BioVie At US$5.44, Meanwhile Stock Sits Near US$3.28

NasdaqCM:BIVI
Source: Shutterstock

BioVie Inc.'s (NASDAQ:BIVI) stock price has dropped 20% in the previous week, but insiders who sold US$225k in stock over the past year have had less luck. Insiders might have been better off holding onto their shares, given that the average selling price of US$5.44 is still below the current share price.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for BioVie

BioVie Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the Independent Director, Richard Jay Berman, sold US$94k worth of shares at a price of US$8.52 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$3.28. So it is hard to draw any strong conclusion from it.

BioVie insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
NasdaqCM:BIVI Insider Trading Volume November 11th 2023

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

BioVie Insiders Are Selling The Stock

The last three months saw significant insider selling at BioVie. Specifically, insiders ditched US$64k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

Does BioVie Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. BioVie insiders own 64% of the company, currently worth about US$71m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The BioVie Insider Transactions Indicate?

Insiders haven't bought BioVie stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 6 warning signs we've spotted with BioVie (including 4 which are significant).

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Valuation is complex, but we're here to simplify it.

Discover if BioVie might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.